Related Experiment Videos
Multiple sclerosis progression in a natural history study: predictive value of cerebrospinal fluid free kappa light
R A Rudick1, S V Medendorp, M Namey
1Department of Neurology (Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Ohio 44106, USA.
Objectives:
To determine the relationship between baseline CSF immunologic abnormalities and MS disease progression; To determine progression rates in an untreated, recently-diagnosed MS sample using several validated clinical measures.
Background:
CSF immune abnormalities are common in MS but have not been linked to disease progression.
Design Methods:
Thirty-six patients with definite (n = 28), probable (n = 2), or possible (n = 6) MS were studied prospectively. Baseline CSF was analyzed for free kappa and lambda light chains, myelin basic protein, IgG synthesis rate, and IgG index. MS patients were entered into the study within 5 years of symptom onset and examined semiannually for as long as 53.4 months (median length of follow up 38.9 months). MS progression was defined as sustained worsening on the following clinical measurement instruments: the Expanded Disability Status Scale (EDSS), the Ambulation Index (AI), the 9 Hole Peg Test (9HT) and the Box and Blocks test (BBT). Kaplan-Meier estimates of disease progression were calculated and the relationship between baseline CSF values and disease progression was determined using Cox proportional hazards regression models.
Results:
By 36 months, 33% (95% CI = 10.3, 55.7) of patients had progressed on EDSS and 49.7% (95% CI = 27.7, 71.7) had progressed on at least one of the outcome measures. Patients with CSF free kappa chain levels in the upper quartile had a significantly higher risk of progression on EDSS (Hazard Ratio 3.78; p = 0.04) and 9HT (Hazard Ratio 10.77, p = 0.04).
Conclusions:
In this study, CSF free kappa light chains predicted subsequent physical deterioration in prospectively evaluated MS patients. If this is confirmed by larger studies, then CSF free kappa light chains could serve as a target for intervention in therapeutic trials.
Insights
Elevated cerebrospinal fluid (CSF) free kappa light chains indicate a higher risk of physical deterioration in multiple sclerosis (MS) patients. This finding may guide future therapeutic interventions for MS progression.
Area of Science:
- Neurology
- Immunology
- Clinical Research
Background:
- Cerebrospinal fluid (CSF) immune abnormalities are frequently observed in multiple sclerosis (MS).
- The direct link between these CSF abnormalities and the progression of MS has not been definitively established.
- Understanding these relationships is crucial for predicting disease trajectory and developing targeted therapies.
Purpose of the Study:
- To investigate the association between baseline CSF immune markers and the progression of MS.
- To quantify disease progression rates in a cohort of untreated, recently diagnosed MS patients.
- To identify specific CSF biomarkers that predict future disability.
Main Methods:
- Prospective study of 36 patients with definite, probable, or possible MS within 5 years of symptom onset.
- Baseline CSF analysis included free kappa and lambda light chains, myelin basic protein, IgG synthesis rate, and IgG index.
- Disease progression was monitored for up to 53.4 months using the Expanded Disability Status Scale (EDSS), Ambulation Index (AI), 9 Hole Peg Test (9HT), and Box and Blocks Test (BBT).
Main Results:
- After 36 months, 33% of patients showed EDSS progression, and 49.7% progressed on at least one clinical measure.
- Patients in the highest quartile of CSF free kappa light chain levels exhibited a significantly increased risk of progression on the EDSS (HR 3.78, p=0.04).
- Elevated CSF free kappa light chains also predicted a higher risk of progression on the 9 Hole Peg Test (HR 10.77, p=0.04).
Conclusions:
- Baseline levels of CSF free kappa light chains are predictive of subsequent physical deterioration in MS patients.
- These findings suggest that CSF free kappa light chains could serve as a valuable biomarker for monitoring MS progression.
- Further validation in larger studies is warranted to confirm CSF free kappa light chains as a potential therapeutic target in MS clinical trials.